In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases.